Compare KeyCorp (KEY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Repligen Corporation Common Stock — how do they compare? KeyCorp trades at $19.83 (market cap $21.25B), while Repligen Corporation Common Stock trades at $178.18 (market cap $11.14B). The key difference: KeyCorp is the larger of the two by market cap, and KeyCorp pays a 4.12% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Repligen Corporation Common Stock for 0 Days on average.
| KEY | RGEN | |
|---|---|---|
Market Cap | $21.25B | $11.14B |
Volume | 17,676,934 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $23.99 | $194.57 |
52-Week Low | $16.78 | $102.87 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $34.43B | $11.02B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.79, down 1.49% on the day, with a bearish technical signal but strong fundamentals including a P/E of 11.64 and net income margin of 26.72%. Recent quarterly earnings have consistently beaten expectations, and the company maintains a $0.21 dividend. Analyst consensus is bullish with a $25.00 price target, though recent news highlights competitive dividend pressures.
The outlook for KEY is positive based on earnings momentum and valuation, but risks include interest rate sensitivity and frozen dividends. Upside potential exists if loan growth and fee income continue to drive revenue, yet investor sentiment is cautious amid technical weakness and macroeconomic uncertainty.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
